


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)



In re Application of

Application Number

09/256388

Filed

2-24-99

Group Art Unit

Examiner

Paper No. 414

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE):

- ☒ (A) referred to in United States Patent Number 6015557, column _____
- ☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____ filed _____, on page _____ of paper number _____
- ☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or
- ☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Ricardo G. Garcia

Signature

RICARDO G. GARCIA

Typed or printed name

02-18-00

Date

FOR PTO USE ONLY

Approved by: [Signature]

(Initials)

Unit: File



US006015557A

United States Patent [19]

Tobinick et al.

[11] **Patent Number:** **6,015,557**[45] **Date of Patent:** **Jan. 18, 2000**

[54] **TUMOR-NECROSIS-FACTOR ANTAGONISTS
FOR THE TREATMENT OF
NEUROLOGICAL DISORDERS**

5,656,272 8/1997 Le et al. .
5,795,967 8/1998 Aggarwal et al. .

[76] **Inventors:** Edward L. Tobinick; Arthur Jerome
Tobinick, both of 100 UCLA Medical
Plz., Suite 205, Los Angeles, Calif.
90024-6903

Primary Examiner—William R. A. Jarvis
Attorney, Agent, or Firm—Ezra Sutton

[57] **ABSTRACT**[21] **Appl. No.:** **09/275,070**[22] **Filed:** **Mar. 23, 1999****Related U.S. Application Data**

[63] Continuation-in-part of application No. 09/256,388, Feb. 24,
1999, abandoned.

[51] **Int. Cl.⁷** A61K 39/395; A61K 31/495;
A61K 31/50; A61K 31/42

[52] **U.S. Cl.** 424/134.1; 514/249; 514/378

[58] **Field of Search** 424/134.1; 514/249,
514/378

A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing damage to neuronal tissue or for modulating the immune response affecting neuronal tissue of the human. The TNF antagonist administered is selected from the group consisting of etanercept and infliximab. The TNF antagonist is administered subcutaneously, intravenously, intrathecally, or intramuscularly.

Methotrexate or Leflunomide may be administered concurrently with the TNF antagonist for demyelinating diseases and certain other neurological disorders.

[56] **References Cited****U.S. PATENT DOCUMENTS**

5,605,690 2/1997 Jacobs et al. .

47 Claims, No Drawings